About Nimbus Therapeutics
Nimbus Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2009. Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. Nimbus Therapeutics has raised $685 million across 12 funding rounds from investors including Pfizer, Schrödinger and Citadel. The company has 81 employees. Its chief executive, as recorded, is Jeb Keiper. Its website nimbustx.com draws about 15 thousand monthly visits. Nimbus Therapeutics offers products and services including TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is NIMBUS DISCOVERY INC. Its competitors include Moderna, BeiGene and Aclaris Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Nimbus Therapeutics was founded in 2009 in Cambridge, United States, within the biotechnology sector. Targeted therapeutics are developed by the company for cancer, metabolic, and inflammatory diseases. The lead candidate is directed at acetyl-CoA carboxylase (ACC) for treating nonalcoholic steatohepatitis (NASH). An additional candidate, an IRAK4 inhibitor, is pursued to address Tyk2 and KRas pathways involved in immune signaling. Operations focus on advancing these programs through research and development.
- Headquarters Cambridge, United States
- Employees 81
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website nimbustx.com
- Social LinkedIn X
- Legal Name Nimbus Discovery Inc.
- Total Equity Funding$685M (USD)
in 12 rounds
- Latest Funding Round$210M (USD), Series F
Sep 2023
- InvestorsPfizer
& 20 more
- Employee Count81
Products & Services of Nimbus Therapeutics
Nimbus Therapeutics offers a comprehensive portfolio of products and services, including TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor.
Inhibitor for immune-mediated diseases through clinical development.
Inhibitor for oncology applications in drug discovery.
Inhibitor targeting liver diseases via partnerships.
Funding Insights of Nimbus Therapeutics
Nimbus Therapeutics has successfully raised a total of $685M across 12 strategic funding rounds. The most recent funding activity was a Series F round of $210 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $685M
- Total Rounds 12
- Last Round Series F — $210M
- First Round $3.5M
(Apr 2010)
- Investors Count 21
Latest 10 of 12 funding rounds of Nimbus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $210M | Series F | – | SR One, Google Ventures | |
| Sep 2022 | $125M | Series E | – | SV Health Investors, Bain Capital Life Sciences | |
| Jul 2021 | $105M | Series D | – | BVF Partners | |
| Oct 2020 | $60M | Series C | – | RA Capital Management, BVF Partners | – |
| Jun 2018 | $65M | Series C | – | Atlas Venture, SR One | – |
| Mar 2015 | $43M | Series B | – | – | |
| Mar 2015 | $43M | Series B | – | Lightstone Ventures, Pfizer Venture Investments | |
| Jun 2011 | $24M | Series A | – | – | |
| Mar 2011 | $1.5M | Series A | – | – | |
| Feb 2011 | $1.5M | Seed | – | – |
21 investors in total: 19 institutional and 2 angel.
Investors in Nimbus Therapeutics
Nimbus Therapeutics has secured backing from 21 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Pfizer, Schrödinger and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Venture capital fund and fund of funds focused on the life science sector | lightstonevc.com | Menlo Park, United States | ||
| gatesfrontier.tcc.mode | ||||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Investment and holding company controlled by Len Blavatnik | accessindustries.com | New York, United States | ||
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States |
Investor details for Nimbus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nimbus Therapeutics
8 people are tracked at Nimbus Therapeutics (1 in leadership, 7 in board & advisors); the tracked headcount is 81.
| Name | Role | Group |
|---|---|---|
Jeb Keiper | CEO | Leadership |
Laura Stoppel | Director | Board & advisors |
Jean George | Director | Board & advisors |
Rajeev Dadoo | Director | Board & advisors |
George P. Vlasuk | Director | Board & advisors |
Mark Iwicki | Director | Board & advisors |
Anne McGeorge | Director | Board & advisors |
Bruce Booth | Director | Board & advisors |
Complete people profiles for Nimbus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nimbus Therapeutics
3 dated milestones of Nimbus Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Nimbus Therapeutics is founded.
- Funding First funding round of $3.5M.
- Funding Latest funding round, Series F, of $210.0M.
Competitors of Nimbus Therapeutics
Nimbus Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Aclaris Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. |
Detailed competitors of Nimbus Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nimbus Therapeutics
The website of Nimbus Therapeutics (nimbustx.com) receives about 15.2K visits a month and ranks #2,193,568 among all websites worldwide, #2,975 in Biotechnology and Pharmaceuticals.
- Monthly visits15.2K
▲ 54.8% vs previous month
- Unique visitors4.5K
per month
- Global rank#2,193,568
among all websites
- Category rank#2,975
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.0
- Average visit12 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Nimbus Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arrowheadpharma.com | 100% | 61.8K | #782,346 | View details | |
jobs.takeda.com | jobs.takeda.com | 86% | #185,912 | – | |
careers.lilly.com | careers.lilly.com | 86% | #60,411 | – | |
| novonordisk.com | 52% | 637.8K | #83,485 | View details |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Nimbus Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nimbus Therapeutics
Complete news archive for Nimbus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nimbus Therapeutics
Nimbus Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Nimbus Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jeb Keiper is the CEO of Nimbus Therapeutics, as recorded in our data.
Nimbus Therapeutics is a funded company, having raised a total of $685M across 12 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Apr 2010.
Nimbus Therapeutics has 81 employees.
Nimbus Therapeutics was founded in 2009 in Cambridge, United States, within the biotechnology sector. Targeted therapeutics are developed by the company for cancer, metabolic, and inflammatory diseases. The lead candidate is directed at acetyl-CoA carboxylase (ACC) for treating nonalcoholic steatohepatitis (NASH). An additional candidate, an IRAK4 inhibitor, is pursued to address Tyk2 and KRas pathways involved in immune signaling. Operations focus on advancing these programs through research and development.
Nimbus Therapeutics's top competitors include Moderna, BeiGene and Aclaris Therapeutics.
Nimbus Therapeutics offers TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor.
Nimbus Therapeutics has 21 investors. Key investors include Pfizer, Schrödinger, Citadel, RA Capital, and GSK.
Nimbus Therapeutics operates through Nimbus Discovery Inc..